1. Home
  2. ALXO vs IROQ Comparison

ALXO vs IROQ Comparison

Compare ALXO & IROQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALXO
  • IROQ
  • Stock Information
  • Founded
  • ALXO 2015
  • IROQ 1883
  • Country
  • ALXO United States
  • IROQ United States
  • Employees
  • ALXO N/A
  • IROQ N/A
  • Industry
  • ALXO Biotechnology: Pharmaceutical Preparations
  • IROQ Savings Institutions
  • Sector
  • ALXO Health Care
  • IROQ Finance
  • Exchange
  • ALXO Nasdaq
  • IROQ Nasdaq
  • Market Cap
  • ALXO 79.7M
  • IROQ 82.7M
  • IPO Year
  • ALXO 2020
  • IROQ 2011
  • Fundamental
  • Price
  • ALXO $1.47
  • IROQ $26.05
  • Analyst Decision
  • ALXO Strong Buy
  • IROQ
  • Analyst Count
  • ALXO 6
  • IROQ 0
  • Target Price
  • ALXO $3.30
  • IROQ N/A
  • AVG Volume (30 Days)
  • ALXO 356.5K
  • IROQ 11.6K
  • Earning Date
  • ALXO 11-07-2025
  • IROQ 10-31-2025
  • Dividend Yield
  • ALXO N/A
  • IROQ 1.54%
  • EPS Growth
  • ALXO N/A
  • IROQ 154.92
  • EPS
  • ALXO N/A
  • IROQ 1.60
  • Revenue
  • ALXO N/A
  • IROQ $27,979,000.00
  • Revenue This Year
  • ALXO N/A
  • IROQ N/A
  • Revenue Next Year
  • ALXO N/A
  • IROQ N/A
  • P/E Ratio
  • ALXO N/A
  • IROQ $16.24
  • Revenue Growth
  • ALXO N/A
  • IROQ 24.68
  • 52 Week Low
  • ALXO $0.40
  • IROQ $21.00
  • 52 Week High
  • ALXO $2.27
  • IROQ $26.50
  • Technical
  • Relative Strength Index (RSI)
  • ALXO 49.39
  • IROQ 58.69
  • Support Level
  • ALXO $1.29
  • IROQ $25.96
  • Resistance Level
  • ALXO $1.56
  • IROQ $26.14
  • Average True Range (ATR)
  • ALXO 0.18
  • IROQ 0.09
  • MACD
  • ALXO 0.01
  • IROQ 0.01
  • Stochastic Oscillator
  • ALXO 65.90
  • IROQ 77.79

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About IROQ IF Bancorp Inc.

IF Bancorp Inc is a holding company mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company, in association, takes deposits from the general public and invests those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, etc., and offers a variety of deposit accounts and alternative delivery channels. In addition to the traditional banking products and services, the group also offers a full line of property and casualty insurance products, annuities, mutual funds, individual securities, managed accounts, and other financial services.

Share on Social Networks: